Biocompatibility of HEMA Copolymers Designed for Treatment of CNS Diseases with Polymer‐Encapsulated Cells

Surrounding the cells with a semipermeable polymeric membrane allows transplanting unmatched xenogeneic cells without a risk of their rejection. We prepared and tested several 2‐hydroxyethyl methacrylate (HEMA) copolymers with alkyl methacrylates or acrylates to find out which was the most valuable for cell encapsulation. On the basis of optimum physical properties and good results of cytotoxicity tests, HEMA‐EMA copolymer was chosen as a suitable candidate for encapsulation and immunoprotection of xenogeneic cells before their grafting into the central nervous system (CNS). To characterize the biocompatibility of p(HEMA‐co‐EMA) copolymer in the CNS, we implanted microcapsules made of this hydrogel into the brains of adult rats that were allowed to survive for 0.5, 1, 3, 6, and 9 months. Analysis of histological sections containing the implantation site was aimed at assessment of the cellular density at the implant‐brain interface and identification of cell types participating in a tissue reaction. Our results indicated that the tissue reaction that was observed was caused largely by the implantation procedure because HLA‐DR‐ and GSI‐B4‐positive macrophages/microglia infiltrated mainly the implantation channel. The number of these cells declined with time, which was true also for GFAP‐positive reactive astrocytes, as well as for foreign body giant cells. The amount of connective tissue components surrounding the implanted microcapsules increased only slightly. These findings indicated that p(HEMA‐co‐EMA) hydrogel was well tolerated after implantation in the brain.

[1]  T. Chang,et al.  Semipermeable Microcapsules , 1964, Science.

[2]  S. Raju,et al.  Immunologic study of the brain as a privileged site. , 1977, Transplantation proceedings.

[3]  C. Barker,et al.  Immunologically privileged sites. , 1977, Advances in immunology.

[4]  K. Weber,et al.  Vimentin, the 57 000 molecular weight protein of fibroblast filaments, is the major cytoskeletal component in immature glia. , 1981, European journal of cell biology.

[5]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[6]  B. Tighe,et al.  Requirements for cell spreading on polyHEMA coated culture substrates. , 1984, Cell biology international reports.

[7]  B. Ratner,et al.  Rat peritoneal macrophage adhesion to hydroxyethyl methacrylate-ethyl methacrylate copolymers and hydroxystyrene-styrene copolymers. , 1985, Journal of biomedical materials research.

[8]  B. Tighe,et al.  Cellular interactions with synthetic polymer surfaces in culture. , 1985, Biomaterials.

[9]  R. Lund,et al.  MHC antigen expression in spontaneous and induced rejection of neural xenografts. , 1990, Progress in brain research.

[10]  S. Kohsaka,et al.  Immunological rejection of grafted tissue in xenogeneic neural transplantation. , 1990, Progress in brain research.

[11]  M. Key,et al.  Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. , 1991, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[12]  Joe C. Adams,et al.  Biotin amplification of biotin and horseradish peroxidase signals in histochemical stains. , 1992, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[13]  J. A. Hubbell,et al.  Poly(ethylene oxide)-graft-poly(L-lysine) copolymers to enhance the biocompatibility of poly(L-lysine)-alginate microcapsule membranes. , 1992, Biomaterials.

[14]  M. Sefton,et al.  Controlled release using microencapsulated mammalian cells , 1992 .

[15]  P. Tresco,et al.  Polymer-encapsulated PC12 cells: long-term survival and associated reduction in lesion-induced rotational behavior. , 1992, Cell transplantation.

[16]  J. Mokrỳ.  Transplantation immunology of the brain as a privileged site for neural grafting. , 1992, Sbornik vedeckych praci Lekarske fakulty Karlovy university v Hradci Kralove.

[17]  Patrick A Tresco,et al.  Polymer-Encapsulated PC12 Cells: Long-Term Survival and Associated Reduction in Lesion-Induced Rotational Behavior , 1992, Cell transplantation.

[18]  M. Sefton,et al.  Morphological assessment of hepatoma cells (HepG2) microencapsulated in a HEMA-MMA copolymer with and without Matrigel. , 1992, Journal of biomedical materials research.

[19]  K. Smetana.  Cell biology of hydrogels. , 1993, Biomaterials.

[20]  M. Sefton,et al.  Microencapsulation of live animal cells using polyacrylates , 1993 .

[21]  B. Finsen.  Microglial reactions following CNS-grafting. , 1993, Clinical neuropathology.

[22]  R. Liem,et al.  Molecular biology of neuronal intermediate filaments. , 1993, Current opinion in cell biology.

[23]  L. Christenson,et al.  Transplantation of Encapsulated Bovine Chromaffin Cells in the Sheep Subarachnoid Space: A Preclinical Study for the Treatment of Cancer Pain , 1994, Cell transplantation.

[24]  P Aebischer,et al.  TRANSPLANTATION IN HUMANS OF ENCAPSULATED XENOGENEIC CELLS WITHOUT IMMUNOSUPPRESSION: A PRELIMINARY REPORT , 1994, Transplantation.

[25]  J. Kordower,et al.  Implants of polymer‐encapsulated human NGF‐secreting cells in the nonhuman primate: Rescue and sprouting of degenerating cholinergic basal forebrain neurons , 1994, The Journal of comparative neurology.

[26]  M. Sefton,et al.  Viability and protein secretion from human Hepatoma (HepG2) cells encapsulated in 400‐μm polyacrylate microcapsules by submerged nozzle–liquid jet extrusion , 1994, Biotechnology and bioengineering.

[27]  R. McLendon,et al.  Immunohistochemistry of the Glial Fibrillary Acidic Protein: Basic and Applied Considerations , 1994, Brain pathology.

[28]  M. Hewicker-Trautwein,et al.  Lectin labelling of amoeboid and ramified microglial cells in the telencephalon of ovine fetuses with the B4 isolectin from Griffonia simplicifolia. , 1994, Journal of comparative pathology.

[29]  P. Aebischer,et al.  Functional Recovery in Hemiparkinsonian Primates Transplanted with Polymer-Encapsulated PC12 Cells , 1994, Experimental Neurology.

[30]  D. Emerich,et al.  Implantation of Polymer-Encapsulated Human Nerve Growth Factor-Secreting Fibroblasts Attenuates the Behavioral and Neuropathological Consequences of Quinolinic Acid Injections into Rodent Striatum , 1994, Experimental Neurology.

[31]  P. Aebischer,et al.  Polymer Encapsulated Cell Lines Genetically Engineered to Release Ciliary Neurotrophic Factor Can Slow Down Progressive Motor Neuronopathy in the Mouse , 1995, The European journal of neuroscience.

[32]  J. Kordower,et al.  Encapsulated PC 12 Cell Transplants into Hemiparkinsonian Monkeys: A Behavioral, Neuroanatomical, and Neurochemical Analysis , 1995 .

[33]  B. Nordlinger,et al.  Permeability and biocompatibility of a new hydrogel used for encapsulation of hepatocytes. , 1995, Biomaterials.

[34]  J. Kordower,et al.  Encapsulated PC12 cell transplants into hemiparkinsonian monkeys: a behavioral, neuroanatomical, and neurochemical analysis. , 1995, Cell transplantation.

[35]  M. Risling,et al.  Rapid, widespread, and longlasting induction of nestin contributes to the generation of glial scar tissue after CNS injury , 1995, The Journal of cell biology.

[36]  V. Karsten,et al.  Cytotoxicity of peritoneal murine macrophages against encapsulated pancreatic rat islets: in vivo and in vitro studies , 1996, Journal of leukocyte biology.

[37]  D. Emerich,et al.  Effects of intraventricular encapsulated hNGF-secreting fibroblasts in aged rats. , 1996, Cell transplantation.

[38]  R. Hauser,et al.  Fetal Nigral Transplantation in Parkinson’s Disease , 1996 .

[39]  B. Říhová,et al.  Biocompatibility of biomaterials: hemocompatibility, immunocompatiblity and biocompatibility of solid polymeric materials and soluble targetable polymeric carriers , 1996 .

[40]  M. Patterson,et al.  Fetal Transplantation for Huntington’s Disease: Clinical Studies , 1998 .

[41]  M. Levivier,et al.  Toward a Phase III Multicenter Study of Fetal Ventral Mesencephalic Transplants in Patients with Late-Stage Parkinson’s Disease , 1998 .

[42]  R. Hauser,et al.  Fetal Nigral Transplantation in Parkinson's Disease: The USF Pilot Program (12- to 24-Month Evaluation) , 1998 .

[43]  H. Widner.  The Lund Transplant Program for Parkinson’s Disease and Patients with MPTP-Induced Parkinsonism , 1998 .

[44]  I. Bechmann,et al.  FasL (CD95L, Apo1L) is expressed in the normal rat and human brain: Evidence for the existence of an immunological brain barrier , 1999, Glia.